ASCO 2018 Annual Meeting Highlights in Multiple Myeloma

ASCO Overview from Saad Z. Usmani, MD, FACP – Run Time: 7:47 Begin

ASCO Highlights from Noopur Raje, MD bb2121 anti-BCMA CAR T cell therapy in RRMM Ex vivo expanded cord blood natural killer cells FDA analysis of pembrolizumab trials Run Time: 9:56 Begin

ASCO Highlights from Sagar Lonial, MD, FACP Phase 2 study: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in RRMM 5-year follow-up phase 3 ELOQUENT-2 (elotuzumab/lenalidomide/dex vs len/dex) in RRMM ALCYONE: Daratumumab plus bortezomib-melphalan-prednisone Phase 3 AQUILA: Subcutaneous daratumumab vs active monitoring in high-risk SMM Run time: 5:44 Begin

ASCO Highlights from Saad Z. Usmani, MD, FACP Pembrolizumab plus lenalidomide/dexamethasone vs len/dex for NDMM: KEYNOTE-185 Subcutaneous daratumumab in RRMM: Dose escalation phase 1b PAVO COLUMBA phase 3 study: Subcutaneous vs IV daratumumab in RRMM Phase Ib results: Isatuximab plus pomalidomide/dex in RRMM Pomalidomide/bortezomib/dex vs bortezomib/dex in RRMM: Phase 3 OPTIMISMM trial Run time: 7:45 Begin

ASCO Highlights from Robert Z. Orlowski, MD, PhD Carfilzomib/dexamethasone vs bortezomib/dex RRMM: ENDEAVOR update Phase 3 IKEMA: Isatuximab/carfilzomib/dex vs carfilzomib/dex in RRMM Phase 3 IMROZ: Isatuximab/bortezomib/len/dex vs bortezomib/len/dex in NDMM Run Time: 6:15 Begin